Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03650348 · ClinicalTrials.gov registry record · Phase 1
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, sponsored by Pieris Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 8
- Study locations
NCT03650348 is a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer that has completed, run by Pieris Pharmaceuticals. The registered enrollment target is 41 participants, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT03650348, a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, has completed, sponsored by Pieris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 8
- Study locations
Study Summary
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG PRS-343 in Combination with Atezolizumab
Study Locations (8)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UCLA Health - Santa Monica
Texas
- M.D. Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Louisiana
- Ochsner Cancer Institute - New Orleans
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2022-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03650348
The ClinicalTrials.gov registry entry for NCT03650348 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Pieris Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PRS-343 in Combination with Atezolizumab is the first listed.
NCT03650348 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03650348 about?
NCT03650348 is a clinical study titled "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors". A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
What is the current status of trial NCT03650348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-08-21. Estimated completion is 2022-08-11.
What conditions does trial NCT03650348 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-Positive Solid Tumor, HER2-positive Bladder Cancer.
What interventions are being tested in trial NCT03650348?
The interventions under investigation include: PRS-343 in Combination with Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03650348?
This trial is sponsored by Pieris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03650348 being conducted?
This trial has 8 study locations across California, Louisiana, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
RECRUITING · Phase 1
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
HER2 Vaccine for Locally Advanced Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.